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CDC, U.S. Food and Drug Administration (FDA), state and local health departments, and
other clinical and public health partners are investigating a multistate outbreak of
severe pulmonary disease associated with e-cigarette product (devices, liquids, refill
pods, and/or cartridges) use. This investigation is ongoing and has not identified a
cause, but all reported cases have a history of using e-cigarette products.
E-cigarettes are devices that deliver an aerosol to the user by heating a liquid that usually
contains nicotine, flavorings, and other chemicals. E-cigarettes can also be used to deliver
marijuana or other substances.
Latest Outbreak Information
As of September 6, 2019, over 450 possible cases of lung illness associated with the
use of e-cigarette products have been reported to CDC from the following 33 states
and 1 U.S. territory: AR, CA, CO, CT, DE, FL, GA, IA, IL, IN, KS, KY, LA, MD, MI, MN,
MT, NC, NE, NJ, NM, NY, OH, OR, PA, SC, TN, TX, UT, VA, VT, WI, WV, and the U.S.
Virgin Islands). These numbers may change frequently.
Five deaths have been confirmed in California, Illinois, Indiana, Minnesota, and
Oregon.
CDC worked with states to create a case definition to classify cases in a consistent
way. State investigators determine if cases are confirmed or probable after examining
the medical records of suspected cases and consulting with the clinical care team to
exclude other possible causes. Unlike nationally reportable conditions, these cases
are requiring clinicians and public health to interview patients to determine product
use and individual behaviors.
CDC will report numbers of confirmed and probable cases once states have finalized
their classification of cases.
We expect that states and clinicians may look back for older cases based on CDC’s
case definition. States are in the process of classifying current possible cases as well
as older cases.
No evidence of infectious diseases has been identified; therefore lung illnesses are
likely associated with a chemical exposure. Initial published reports from the
investigation point to clinical similarities among cases. Patients report e-cigarette use
and similar symptoms and clinical findings. These align with the CDC health advisory
released August 30, 2019.
The investigation has not identified any specific substance or e-cigarette product that
is linked to all cases. Many patients report using e-cigarette products with liquids that
contain cannabinoid products, such as tetrahydrocannabinol (THC).
These investigations are ongoing. CDC will provide updates when more information is
available.
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Recommendations for the Public
While this investigation is ongoing, consider not using e-cigarette products.
If you do use e-cigarette products and you experience symptoms like those reported in this
outbreak, seek medical care promptly. CDC and the FDA will continue to alert the public
throughout this investigation.
Regardless of the ongoing investigation:
Youth and young adults should not use e-cigarette products.
Women who are pregnant should not use e-cigarette products.
Adults who do not currently use tobacco products should not start using e-cigarette
products.
If you do use e-cigarette products, you should not buy these products off the street
(for example, e-cigarette products with THC or other cannabinoids).
You should not modify e-cigarette products or add any substances to these products
that are not intended by the manufacturer.
Adult smokers who are attempting to quit should use evidence-based treatments,
including counseling and FDA-approved medications. If you need help quitting
tobacco products, including e-cigarettes, contact your doctor or other medical
provider.
If you are concerned about your health after using an e-cigarette product, you can also call
your local poison control center at 1-800-222-1222.
CDC and FDA encourage the public to submit detailed reports of any unexpected health or
product issues related to tobacco or e-cigarette products to the FDA via the online Safety
Reporting Portal.
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Symptoms of Severe Pulmonary Disease Reported by Some Patients in This Outbreak
Patients in this investigation have reported symptoms such as:
cough, shortness of breath, or chest pain
nausea, vomiting, or diarrhea
fatigue, fever, or weight loss
Some patients have reported that their symptoms developed over a few days, while
others have reported that their symptoms developed over several weeks. A pulmonary
infection does not appear to be causing the symptoms, which have generally not
improved with antibiotic treatment alone.
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Recommendations for Healthcare Providers
As this investigation continues, CDC encourages clinicians to report possible cases of e-
cigarette-associated pulmonary disease to their local or state health department for further
investigation.
If e-cigarette product use is suspected as a possible cause for a patient’s lung disease, a
detailed history of the substances used, the sources, and the devices used should be
obtained, as outlined in the HAN, and efforts should be made to determine if any remaining
product, devices, and liquids are available for testing.
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Recommendations for Local and State Public Health Departments
CDC encourages local and state health departments to notify CDC about possible cases
promptly, and contact CDC for the most recent versions of the surveillance case definitions,
reporting guidelines, and case investigation forms.
Local and state public health departments that need data collection tools should email CDC
at eocevent101@cdc.gov.
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Investigation Details
August 30, 2019
CDC, several states, and federal partners are investigating a multistate outbreak of severe
pulmonary disease associated with using e-cigarette products. The investigation is ongoing
and has not identified a cause, but all reported cases have indicated use of e-cigarette
products.
Based on reports from several states, patients have experienced respiratory symptoms
(cough, shortness of breath, or chest pain), and some have also experienced gastrointestinal
symptoms (nausea, vomiting, or diarrhea) or non-specific symptoms (fatigue, fever, or weight
loss). Some patients have reported that their symptoms developed over a few days, while
others have reported that their symptoms developed over several weeks. Some patients have
reported gastrointestinal symptoms began before respiratory symptoms. Fever, elevated
heart rate, and elevated white blood cell count have been reported, even though no infectious
disease has been identified. Many patients sought medical care in ambulatory settings,
sometimes over several visits, before they were admitted to the hospital.
Many patients have required medical treatment with supplemental oxygen. Some required
assisted ventilation. Some patients have been treated with corticosteroids with demonstrated
improvement. Evidence does not suggest an infectious disease is the cause of the severe
pulmonary disease. Antibiotic therapy alone has not consistently been associated with
clinical improvement.
Investigation of the Outbreak
CDC, FDA, state and local health departments, and other clinical and public health partners
are investigating a multistate outbreak of pulmonary disease associated with e-cigarette
product (devices, liquids, refill pods, and/or cartridges) use. This ongoing investigation seeks
to identify the exposures, demographic, clinical, and laboratory features and behaviors of
patients. All patients have reported e-cigarette product use. Some patients have reported
using e-cigarettes containing cannabinoid products, such as THC. To date, the investigation
has not identified any single substance or e-cigarette product that has been consistently
associated with illness.
State health departments are working with FDA to enable collection of e-cigarette product
specimens for testing at the U.S. FDA Forensic Chemistry Center.
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